Thermo Fisher Scientific Inc.

“Thermo Fisher is the critical infrastructure layer of global life sciences — a wide-moat, consumables-driven platform with durable margins and a multi-decade secular growth runway in biologics and cell/gene therapy. The business earns strong returns on capital, generates >$7B in annual free cash flow, and is led by a proven capital allocator with a 15-year track record. The investment case is not in question; the price is. At 18.5x EV/EBITDA and 18x forward earnings, the market prices in a full recovery cycle, leaving limited margin of safety against the primary structural risks: US-China decoupling eroding ~10% of revenues, NIH funding attrition in US academic end-markets, and tariff-driven margin pressure. A 15-20% price decline would shift the risk/reward to a high-conviction BUY; at current levels, TRACK and accumulate in small tranches.”